Kinled invests its own money. Now you can co-invest.
Invest in the deals a fourth-generation company has already backed with family capital.
Take an Allocation
£25k
Entry level, through an FCA-regulated fund
Speak to the Private Client Team
Capital at risk. Unlisted early-stage investments are illiquid, and you may lose all the money you invest.
1924
Investing since
200+
Investments made
60
Company exits
21
IPOs achieved
1924
The Aisher family
A creator of wealth since 1924.
The Aisher family began investing in 1924. A century later, it is still investing, now in its fourth generation. Along the way the family built an industrial group that, by 1999, employed 13,000 people across 59 countries. That experience spans generations, industries and economic cycles.
Today that entrepreneurial instinct drives Kinled, the family's privately owned Anglo-Austrian holding company. Kinled backs the scientists and founders turning research into commercial businesses in life sciences, digital technology and fintech. It takes an active hand in building each business. In 2023 it opened a Private Client Division so that eligible investors can join it.
Four generations of the Aisher family
Owen Aisher1876-1963
Sir Owen Aisher1900-1993
Jack Aisher1910-2008
Patrick AisherChairman of Kinled
The family commits its own capital first. You invest alongside it, with its money at stake too.
Investment record
Thousands of plans reviewed. A handful backed.
Kinled turns down almost everything it sees. The companies that make it through have survived one of the toughest filters in private markets.
How a company earns Kinled's capital
2,000+business plans reviewed every year
150taken through deep legal and commercial due diligence
2-4new companies typically backed each year
1-2exits in a typical year
Selected sales and IPOs
Sale
Sale
Sale
Sale
Sale
IPO
IPO + Sale
Sale
Sectors and research focus
Where your capital goes
Kinled concentrates on three sectors where deep technology is changing markets. About 90% of its investment is made directly into companies. Its deal flow starts in university laboratories across Europe and the United States, well before most investors hear of these companies.
Over 50%of the portfolio
Life sciences
Medical devices, robotics, neuromodulation, precision medicine, drug discovery and digital healthcare services
25%of the portfolio
Digital technologies
SaaS-enabled networks and marketplaces, with a strong emphasis on digital health
25%of the portfolio
Fintech
Technology challenging established institutions in payments, insurance, real estate, lending and banking
Where deals begin
3Three venture accelerators across Austria and Switzerland, turning research into businesses
8Early-stage spinouts from eight universities, including Zürich, Geneva, Lausanne, Graz and Vienna
1616 portfolio businesses in the United States, often co-invested with specialist partners
6Six international offices, including Hong Kong, Switzerland, Austria, London and Shanghai
1010 specialist fund partnerships, with €525M combined assets under management across those funds
Your route
Co-invest alongside Kinled from £25k
Take an allocation
Entry level
£25k
Structure
An allocation via an FCA-regulated fund
Alongside
A holding company that has already committed its own capital
What happens next
1
Register your interest
Share your details and choose a time that suits you for a callback.
2
Take the call
A member of the private client team confirms your eligibility as an investor.
3
Review the pack
Eligible investors receive the full investor pack and details of current opportunities.
A century of family capital. Your place alongside it from £25k.
